Endocrine-disrupting chemicals (EDCs) in plastics pose a serious threat to public health and cost the U.S. an estimated $250 billion in increased healthcare costs in 2018, according to new research published in the Journal of the Endocrine Society. Plastics contain many hazardous, endocrine-disrupting chemicals that leach and contaminate humans and the environment. These chemicals disturb the body’s...
The Endocrine Society is advocating for you. In 2023 we achieved several important advocacy accomplishments, including: All these accomplishments were achieved because our members participated in our advocacy activities, online campaigns, Hill Days, and meetings with policymakers. Below are some examples of our advocacy victories. Advocacy to Lower the Cost of Insulin – The Endocrine Society...
Endocrine Society member and medical director for Endocrinology for Veracyte, Joshua Klopper, MD, talks to Endocrine News about a new tool that may have the potential to guide thyroid cancer management decisions by predicting tumor behavior via molecular signatures. In “New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Baseline Characteristics Reported from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH Spruce Biosciences, Inc., today reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH)....
Study links high blood sugar during pregnancy with weak heart health A new Journal of the Endocrine Society study among women attending a fertility center found that those with more stress before pregnancy had higher blood sugar levels during pregnancy, which is a sign of weaker cardiovascular health. People’s stress levels have continued to rise over the...
J. Larry Jameson, MD, PhD, was named interim president of the University of Pennsylvania in a unanimous motion by the school’s board of trustees last month. Jameson had previously served as dean of Penn’s Perelman School of Medicine. “Penn is a remarkable institution that I am honored and humbled to lead and serve,” Jameson says. “Penn, like...
The Endocrine Society applauds Governor Mike Dewine’s veto of a proposed Ohio law that would have banned gender-affirming care for minors. The bill he vetoed contradicts mainstream medical practice and scientific evidence and would have taken medical decision-making out of the hands of families and their physicians and instead relied upon government officials. More than...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency On December 19, Ascendis Pharma announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled...
J. Larry Jameson, MD, PhD, was named interim president of the University of Pennsylvania in a unanimous motion by the school’s board of trustees last month. Jameson had previously served as dean of Penn’s Perelman School of Medicine. “Penn is a remarkable institution that I am honored and humbled to lead and serve,” Jameson says. “Penn, like...
